IQVIA Holdings consensus stays constructive, shares trade near record territory

IQVIA Holdings enters the end of the week with a solid Wall Street consensus and only limited distance to its 52?week high on the NYSE, while analysts see further earnings growth ahead.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 10:23.

IQVIA Holdings (US46266C1053) enters Friday trading on the NYSE with a broadly positive analyst stance and shares not far from their 52-week high, according to recent market data from New York.

What analysts are saying

According to a Reuters consensus overview, more than 20 covering analysts currently rate IQVIA between Hold and Buy, with the majority in the Buy camp and only a small minority on Sell. Recent notes from large houses such as Morgan Stanley and JPMorgan highlight the company’s role as a key contract research and data partner to global pharma peers like Thermo Fisher and Labcorp.

Research aggregation pages on MarketScreener show an average 12?month price target that sits meaningfully above the latest NYSE close, implying a double?digit percentage upside based on the current level of IQVIA shares.MarketScreener consensus data The spread of estimates remains relatively tight, pointing to a clear, constructive view on the stock’s earnings trajectory over the coming quarters.

Focus on earnings growth and margins

In its most recent quarterly update for the March period, IQVIA reported mid?single?digit revenue growth and a further expansion of adjusted EBITDA margins, supported by demand from large pharma and biotech customers, according to company filings and NYSE commentary.IQVIA Q1 2026 results release Analysts followed up by nudging earnings estimates higher, citing a solid backlog and recurring data revenue.

Market commentators at Bloomberg note that IQVIA’s mix of technology?enabled clinical services and real?world data has helped to keep revenue growth above that of many traditional contract research names, while also supporting cash generation for potential shareholder returns.Bloomberg analysis on IQVIA outlook This operational profile features prominently in analyst models, where 2026 and 2027 earnings per share are projected to grow at a high single?digit to low double?digit rate.

How IQVIA earns its money

IQVIA generates revenue primarily from three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions, with the first two contributing the bulk of sales as reported in its latest annual filing.IQVIA annual report The company sells subscription?based real?world data sets, analytics platforms and clinical trial services to pharmaceutical, biotech and healthcare customers worldwide.

Where the stock trades today

IQVIA Holdings shares (US46266C1053) last traded on the NYSE at around 240 US dollars as of 2026-06-25, 22:00, according to exchange data from New York.

Key data on the IQVIA Holdings shares

• Company: IQVIA Holdings Inc.
• ISIN: US46266C1053
• WKN: A2JE4W
• Ticker: IQV
• Trading venue: NYSE
• Price (as of 2026-06-25, 22:00): 240.00 USD
• Market cap: 43,000,000,000 USD (as of 2026-06-25)
• Sector / industry: Health Care – Life Sciences Tools & Services
• Index membership: S&P 500
• Next earnings date: 2026-07-24

This text is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any securities. All data points are based on publicly available sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research and consider their individual financial situation before making investment decisions.